Scleroderma Renal Crisis in Mixed Connective Tissue Disease

Area of Science:

• Nephrology
• Rheumatology
• Vascular Medicine

Background:

• Scleroderma renal crisis (SRC) is a severe vascular complication primarily linked to systemic sclerosis.
• Its occurrence in mixed connective tissue disease (MCTD) is exceptionally rare, with only 10 documented cases.
• SRC pathogenesis involves endothelial damage, intimal hyperplasia, and arteriolar narrowing, causing malignant hypertension and hemolytic anemia.

Purpose of the Study:

• To highlight the rare occurrence and clinical characteristics of scleroderma renal crisis in mixed connective tissue disease.
• To emphasize the importance of early diagnosis and management of SRC in MCTD patients.
• To discuss current and emerging therapeutic strategies for SRC.

Main Methods:

• Literature review of reported cases of SRC in MCTD.
• Analysis of clinical presentation, pathogenesis, and treatment outcomes.
• Review of current management guidelines and novel therapeutic approaches.

Main Results:

• SRC in MCTD presents with severe hypertension and often microangiopathic hemolytic anemia.
• Angiotensin-converting enzyme inhibitors (ACEi), particularly captopril, are the cornerstone of management.
• Despite treatment, a significant proportion of patients may develop end-stage renal disease.

Conclusions:

• Early recognition and prompt initiation of ACE inhibitors are critical for managing SRC in MCTD.
• Emerging therapies like endothelin receptor antagonists and complement inhibitors show promise for refractory cases.
• Increased awareness of SRC in MCTD is essential for improving patient outcomes and preventing irreversible renal damage.